Simian immunodeficiency virus protease (SIV protease) (SIV PR)

Simian immunodeficiency virus (SIV) protease is a homodimeric aspartic protease essential for the replication cycle of SIV, a retrovirus that infects non-human primates and serves as the primary animal model for HIV/AIDS (UniProt: P03366). The enzyme is responsible for the post-translational processing of the Gag and Gag-Pol polyprotein precursors into mature structural proteins (MA, CA, NC, p6) and essential enzymes, including protease, reverse transcriptase, and integrase (PubMed: 1564633). This cleavage occurs during or shortly after the budding of the immature virus from the host cell, a step known as viral maturation, which is required for the virus to become infectious (PubMed: 11114201). Due to its high structural and functional homology with HIV-1 protease, SIV protease is a major focus in antiretroviral research and drug testing. Most clinical HIV protease inhibitors, such as darunavir and saquinavir, also exhibit inhibitory activity against SIV protease, although differences in the binding pocket can lead to variations in drug sensitivity and resistance profiles (PubMed: 16105923). Inhibition of this enzyme prevents the formation of infectious virus, making it a primary target for antiviral drug development and research into overcoming viral resistance.

Other names

SIV retropepsinSimian immunodeficiency virus aspartic proteaseSIV aspartyl proteaseSIV PR

Competitive inhibition of the aspartic protease active site, which prevents the proteolytic cleavage of Gag and Gag-Pol polyprotein precursors into mature, functional viral proteins (PubMed: 1564633).